Abstract
As the considerable technical challenges involved with generating crystal structures of G (guanine nucleotide- binding) protein-coupled receptors (GPCRs) are starting to be successfully addressed, opportunities to apply fragment-based drug discovery (FBDD) to this class of target are becoming a reality. GPCRs represent a large and important family of drug targets with considerable clinical and commercial interest. While their general seven transmembrane helix bundle structures are amenable to therapeutic intervention with small molecules, to date successful drugs have primarily been discovered using traditional competitive or function-based screening. With advances in biophysical screening techniques such as Surface Plasmon Resonance (SPR) and Target-Immobilised NMR Screening (TINS), being matched to developments in molecular dynamics simulations, virtual screening and stabilisation of biologically relevant conformations of GPCRs, structure-based approaches using fragment starting points are beginning to be applied to the discovery of new generations of small molecules.
Keywords: FBDD, Fragment-based drug discovery, Fragments, GPCR, G Protein-coupled receptors, Small molecules.
Graphical Abstract
Current Topics in Medicinal Chemistry
Title:G Protein-Coupled Receptors - Targets for Fragment-based Drug Discovery
Volume: 15 Issue: 24
Author(s): Alastair D.G. Lawson
Affiliation:
Keywords: FBDD, Fragment-based drug discovery, Fragments, GPCR, G Protein-coupled receptors, Small molecules.
Abstract: As the considerable technical challenges involved with generating crystal structures of G (guanine nucleotide- binding) protein-coupled receptors (GPCRs) are starting to be successfully addressed, opportunities to apply fragment-based drug discovery (FBDD) to this class of target are becoming a reality. GPCRs represent a large and important family of drug targets with considerable clinical and commercial interest. While their general seven transmembrane helix bundle structures are amenable to therapeutic intervention with small molecules, to date successful drugs have primarily been discovered using traditional competitive or function-based screening. With advances in biophysical screening techniques such as Surface Plasmon Resonance (SPR) and Target-Immobilised NMR Screening (TINS), being matched to developments in molecular dynamics simulations, virtual screening and stabilisation of biologically relevant conformations of GPCRs, structure-based approaches using fragment starting points are beginning to be applied to the discovery of new generations of small molecules.
Export Options
About this article
Cite this article as:
Lawson D.G. Alastair, G Protein-Coupled Receptors - Targets for Fragment-based Drug Discovery, Current Topics in Medicinal Chemistry 2015; 15 (24) . https://dx.doi.org/10.2174/1568026615666150701113151
DOI https://dx.doi.org/10.2174/1568026615666150701113151 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacokinetics, Organ Toxicity and Antitumor Activity of Docetaxel Loaded in Folate Targeted Cholesterol Based Micelles
Current Drug Delivery Synthesis, Docking and Anti-Tumor Activity of β-L-1,3-Thiazolidine Pyrimidine Nucleoside Analogues
Medicinal Chemistry Elucidation of S-Allylcysteine Role in Inducing Apoptosis by Inhibiting PD-L1 Expression in Human Lung Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Alkyl Chloroformates in Sample Derivatization Strategies for GC Analysis. Review on a Decade Use of the Reagents as Esterifying Agents
Current Pharmaceutical Analysis Alcohol Induced Hepato Cardiotoxicity and Oxidative Damage in Rats: The Protective Effect of n-butanol Extract of Green Tea (Camellia sinensis (L.) Kuntze)
Cardiovascular & Hematological Disorders-Drug Targets Peptidyl Prolyl Isomerase, Pin1 is a Potential Target for Enhancing the Therapeutic Efficacy of Etoposide
Current Cancer Drug Targets Synthesis of New A-CD Estrogenic Compounds: D-Homo-analogs Lacking B-ring
Current Organic Chemistry The Role of Atelocollagen-Based Cell Transfection Array in High- Throughput Screening of Gene Functions and in Drug Discovery
Current Drug Discovery Technologies A Review of Current Animal Models of Osteoarthritis Pain
Current Pharmaceutical Biotechnology Current Translational and Clinical Challenges in Advanced Hepatocellular Carcinoma
Current Medicinal Chemistry High Frequency of the Opioid Receptor µ-1 (OPRM1) A118G Polymorphism, an Opioid Drug Therapy Related Gene, in the Indonesian Population
Current Pharmacogenomics and Personalized Medicine Synthesis and Enzymological Characterization of Some 2-(Substitutedphenylamino) quinazolin-4(3H)-one Derivatives as Potent α-Glucosidase Inhibitors In Vitro
Letters in Drug Design & Discovery Biomarker Assessment in Nutritional Modulation of Oxidative Stress-Induced Cancer Development by Lipid-Related Bioactive Molecules
Recent Patents on Anti-Cancer Drug Discovery Cubosomes: Versatile Nanosized Formulation for Efficient Delivery of Therapeutics
Current Drug Delivery A Novel Task Specific & Thermally Stable Ionic Liquid (TBA Acetate) for the Synthesis of Pyran Annulated Heterocyclic System
Letters in Organic Chemistry Redox-Sensitive Smart Nanosystems for Drug and Gene Delivery
Current Organic Chemistry Investigation of In Vitro Antioxidant Activity and In Vivo Antipyretic and Anti-Inflammatory Activities of Algerian Eryngium campestre L.
Current Bioactive Compounds Effects of Highly Active Antiretroviral Therapy on HIV-1-Associated Oral Complications
Current HIV Research Recent Advances in Substrate Identification of Protein Kinases in Plants and Their Role in Stress Management
Current Genomics Novel Purine Nucleoside Analogues for Hematological Malignancies
Recent Patents on Anti-Cancer Drug Discovery